UroGen Pharma (URGN) said Tuesday that new data from a long-term, follow-up study showed that patients with urothelial cancer who achieved a complete response to primary treatment with the company's Jelmyto chemoablation therapy had a median duration of response of 47.8 months following their initial treatments.
The study enrolled 71 patients with low-grade, upper tract urothelial cancer, including 41 people who achieved complete response after being treated with Jelmyto.
The company said prior research indicated the primary treatment goal for the patient population would be managing relapse and preserving organ function because of the low risk of disease progression.
UroGen also said that investigators were continuing to explore Jelmyto's potential to treat urothelial cancer and are now enrolling participants from the company's uTRACT registry to gather longitudinal data about its real-world usage.
Price: 12.22, Change: -0.26, Percent Change: -2.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.